VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Comparison

NDV-BC/S vaccine NDV-VF/S vaccine
Vaccine Information Vaccine Information
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Monkey
  • Host Species as Laboratory Animal Model: Monkey
  • Antigen: Full-length 1,255-aa SARS-CoV S protein (DiNapoli et al., 2007)
  • Vector: Newcastle disease virus Beaudette C strain (NDV-BC) (DiNapoli et al., 2007)
  • Immunization Route: intranasal immunization
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Monkey
  • Antigen: Full-length 1,255-aa SARS-CoV S protein (DiNapoli et al., 2007)
  • Vector: Lentogenic LaSota strain modified that cleavage sequence of F protein replaced with NDV-BC. (DiNapoli et al., 2007)
  • Immunization Route: intranasal immunization
Host Response Host Response

Monkey Response

  • Host Strain: African Green Monkey
  • Vaccination Protocol: Monkeys were vaccinated with 10^7 pfu of the recombinant virus days 0 and 28 (the two-dose groups) or on day 0 only (the one-dose group). (DiNapoli et al., 2007)
  • Immune Response: Induced neutralizing antibodies, Produced S-specific antibodies, Increase in CD8+ T cells creating IFN-γ and TNF-α1 (DiNapoli et al., 2007)
  • Challenge Protocol: 28 days after the second dose, they were challenged by the i.n. and i.t. routes with SARS-CoV at a tissue culture 50% infectious dose (TCID50) of 10^6 per site. (DiNapoli et al., 2007)
  • Efficacy: Protected (DiNapoli et al., 2007)
  • Description: Exhibited average reductions in viral titer of 13-fold, 276-fold, and 1,102-fold in the nasal turbinate, trachea, and lung, respectively. (DiNapoli et al., 2007)

Monkey Response

  • Host Strain: African Green Monkey
  • Vaccination Protocol: Monkeys were vaccinated with 107 pfu of the recombinant virus days 0 and 28 (the two-dose groups) or on day 0 only (the one-dose group). (DiNapoli et al., 2007)
  • Immune Response: Induced neutralizing antibodies, Produced S-specific antubodies, Increase in CD8+ T cells creating IFN-γ and TNF-α1 (DiNapoli et al., 2007)
  • Challenge Protocol: 28 days after the second dose, they were challenged by the i.n. and i.t. routes with SARS-CoV at a tissue culture 50% infectious dose (TCID50) of 10^6 per site. (DiNapoli et al., 2007)
  • Efficacy: Protected (DiNapoli et al., 2007)
  • Description: Immunization with NDV-VF/S resulted in a 5-fold and 61-fold reduction in nasal turbinate and tracheal SARS-CoV titers, respectively, compared with the control animals. (DiNapoli et al., 2007)
References References
DiNapoli et al., 2007: DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(23); 9788-9793. [PubMed: 17535926].
DiNapoli et al., 2007: DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(23); 9788-9793. [PubMed: 17535926].